Good day, and thank you for standing by. Welcome to the Silk Road Medical third quarter 2023 conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising you that your hand is raised. To withdraw your question, please press star one one again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Marissa Bych, with the Gilmartin Group, Director of Investor Relations. Marissa, please go ahead. Great, thank you for joining today's call. Earlier today, Silk Road Medical released financial results for the three months ended September 30, 2023. A copy of the press release is available on the company's website. Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the federal securities laws, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results, or performance are forward-looking statements. All forward-looking statements, including, without limitation, those relating to our operating trends and future financial performance, expense management, expectations for hiring and growth in our organization and our business, physician training and adoption, market opportunity and penetration, commercial and international expansion, regulatory approvals, reimbursement, competition, and product development, are based upon our current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements. Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our business, please refer to the Risk Factors section of our latest quarterly report on Form 10-Q, filed with the Securities and Exchange Commission. This conference call contains time-sensitive information and is accurate only as of the live broadcast today, November 8, 2023. Silk Road Medical disclaims any intention or obligation, except as required by law, to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. I will now turn the call over to Jack Lasersohn, Chairman of Silk Road Medical's Board of Directors. Good afternoon, everybody, and thank you for joining us. I am the Chairman of Silk Road Medical and have been a Director on the Board for over 15 years. I wanted to start our call today by welcoming Chas McKhann, our new Chief Executive Officer, and offering my excitement for the future of the company. Chas is on the line with us today and alongside Lucas Buchanan, our Chief Financial Officer and Chief Operating Officer. I will turn the line over to Lucas shortly to review our recent performance and drivers of the business. But first, I would like to thank Erica Rogers for her tremendous contributions to the company over the past 11 years. To date, more than 75,000 patients have benefited from the TCAR procedure, which speaks to the incredible impact that the team here at Silk Road has had. Erica has been instrumental in cultivating an enduring mission-focused culture at Silk Road and setting the company apart. We appreciate her leadership and wish her the very best looking forward. Meanwhile, we are thrilled to welcome Chas McKhann to the company. Chas has more than 25 years of experience in the medical device industry, with over 20 years in C-suite positions, building and scaling commercial businesses. Most recently, Chas served as President and CEO of Apollo Endosurgery, which was acquired by Boston Scientific in April of this year. At Apollo, Chas created and led a transformational growth strategy for the company's minimally invasive technologies for gastrointestinal and bariatric conditions. Previously, he held commercial officer roles at Torax Medical and Intersect ENT, as well as leadership positions at Boston Scientific and Johnson & Johnson. We're confident that Chas is the right leader, alongside Lucas and the full leadership team, to leverage our strong infrastructure, skilled commercial team, and substantial body of clinical evidence to take the company further on the journey to treat patients with carotid artery disease. Under his leadership, Silk Road remains committed to the same mission, vision, and values that have guided us since its founding. We look forward to executing a smooth transition and continue expanding our impact for patients. Our company faces a substantial underpenetrated market opportunity, and we will continue to prioritize the growth and adoption of TCAR in this context. With that, I'll turn the line over to Lucas to review third-quarter performance and trends in the business. Thank you. Thanks, Jack. As communicated in our pre-announcement, we achieved third-quarter revenue of $44.4 million, representing 19% year-over-year growth and approximately 6,350 TCAR procedures, representing 20% year-over-year growth. Our results were primarily driven by strong TCAR growth and adoption, offset by pockets of weaker-than-anticipated procedural volume. Our commercial team, across approximately 85 territories today, is hard at work to build upon their physician relationships and strengthen adoption trends in areas where we have seen variability. Chas and I plan to spend substantial time digging into our commercial performance, including a comprehensive review of trends and drivers of physician behavior and adoption over the coming months. For the full year of 2023, we continue to expect revenue of $170 million-$174 million, representing 23%-26% growth over the prior year. I would now like to shift to touch briefly on CMS coverage dynamics. Early in the fourth quarter, CMS released their national coverage decision for carotid stenting procedures. The final decision was largely consistent with their July proposed ruling, extending coverage to both high and standard surgical risk patients that are either asymptomatic, with greater than 70% stenosis, or symptomatic, with greater than 50% stenosis. The final decision was in line with our expectations, and our perspective on the implications for our business remain unchanged. The primary takeaway from this proposal is access, broader access to less invasive options for patients with carotid artery disease, including for underserved and underdiagnosed populations. We see expanded coverage as an indicator of the importance of treating carotid disease, with the likely impact of more awareness and interest in screening, yielding more diagnoses and procedures over time. We are proud of the incredible body of TCAR clinical evidence generated in just the last few years that helped support CMS's decision. With broad reimbursement coverage and broad FDA labeling, the industry's only commercial infrastructure dedicated to carotid disease, and significant experience born from over 75,000 procedures performed to date, we believe our opportunity is vast, and we are confident that TCAR's value proposition will carry the procedure to standard of care in the long run. Shifting to our pipeline initiatives. Last year, we achieved FDA label expansion to standard surgical risk patients for our ENROUTE stent and initiated a large post-approval study called ROADSTER III, which will yield prospective data in this patient population. Enrollment is tracking to our expectations, and we are excited about our progress in this study. Earlier this year, we launched the 5th product in our TCAR portfolio, the Enflate balloon, which is the only balloon purpose-built for carotid arteries in the TCAR procedure. We have entered the market with a premium pricing strategy, and utilization continues to ramp. Looking ahead, we are planning for the upcoming launches of our next-generation neuroprotection system, as well as tapered configurations of our stent, and look forward to sharing more detail when appropriate. Our R&D and clinical organizations continue to progress other ongoing and new programs to maintain and extend our position as the leaders in carotid disease. Lastly, I will review our financial results for the quarter in greater detail. As mentioned, revenue for the three months ended September 30th, 2023, was $44.4 million, a 19% increase from $37.4 million in the same period of the prior year. The number of TCAR procedures in the quarter was approximately 6,350, equating to a 20% increase from the same period of the prior year. Growth in revenue and procedures over the prior year period were driven by increasing TCAR demand. Gross margin for the third quarter of 2023 was 73%, compared to 75% in the third quarter of 2022. The decrease was driven by a revaluation of standard costs in the prior year period, which benefited margins, as well as higher manufacturing costs associated with having two manufacturing facilities fully operational in the third quarter of 2023. Total operating expenses for the third quarter of 2023 were $46.1 million, a 24% increase from $37.3 million in the third quarter of 2022. R&D expenses for the third quarter of 2023 were $10.0 million, compared to $8.5 million in the third quarter of 2022. Sales, general, and administrative expenses for the third quarter of 2023 were $36.0 million, compared to $28.8 million in the third quarter of 2022. The increase was largely driven by growth in personnel and personnel-related expenses and continued commercial expansion. Net loss for the third quarter was $12.8 million, or a loss of $0.33 per share, as compared to a net loss of $10.3 million, or a loss of $0.29 per share, for the same period of the prior year. We ended the quarter with over $197 million in cash, cash equivalents, and investments. We are confident that we can accomplish our current growth and organizational objectives, including executing on our pathway to profitability with our current capital. Finally, I'll echo Jack's remarks: We are incredibly excited to have Chas on board, and we are looking forward to delivering together for patients, providers, and shareholders. Our long-term belief in the value of TCAR remains steadfast, and we are confident that we can drive meaningful value through deeper penetration. With that, I'll turn the line over to Chas for a brief introduction. Thank you, Jack and Lucas, for the warm welcome, and thank you all for joining us today. It truly is an honor and a pleasure to step into the CEO role here at Silk Road Medical. I've been fortunate to lead several businesses in my 25-year career in med tech, and I'd like to highlight one commonality that has really inspired me throughout my career and is one of the reasons why I came here, and that is the potential for innovative, minimally invasive therapies to dramatically improve patient outcomes, especially in very large disease states and end markets. But for me, Silk Road Medical also has a very personal appeal. I come from a family of brain physicians. My father was the Founding Chairman of Neurology at Johns Hopkins, starting back in 1969. Over more than 50 years, he and his colleagues built arguably one of the leading neurology departments in the world. Of course, I'm a little bit biased. My brother followed in his footsteps and is a neurosurgeon at Columbia. So brain health has been very much part of our family for many, many years. But later in life, starting about 10-15 years ago, my father suffered from a series of debilitating strokes, and we experienced stroke as patients and caregivers. Had TCAR been available, I really believe he may have been an excellent candidate for the procedure. And so Silk Road Medical's mission to reduce the risk and impact of stroke is very meaningful and personal to me. In addition to the tremendous impact that we can make for patients, I choose to take this role because of the unmatched benefits of the TCAR procedure, as well as the immense opportunity that we still have in front of us, the strengths of the business, the unique company and culture that Erica, Jack, Lucas, and the rest of the Silk Road leadership team have created over the past decade and more. There is a significant opportunity ahead to establish TCAR as the standard of care in carotid artery disease. I have admired the innovation and growth that Silk Road has achieved over the years, and I am very excited for the journey ahead. I look forward to diving into the business with Lucas, the broader leadership team, and our board, as well as connecting with many of you over the months ahead. With that, we'll turn it over back to the operator, to Stacy, for questions, and Lucas and I are here and happy to address them. Thank you. As a reminder, at this time, we will conduct a question-and-answer session. To ask a question, you will need to press star one one on your telephone and wait for your name to be announced. To withdraw your question, please press star one one again. Please limit to one question and one follow-up question. Please stand by while we compile the Q&A roster. Our first question comes from Rick Wise of Stifel. Rick, please go ahead with your question. Hey, Lucas. Hi, Chas. Welcome to Silk. This is John on for Rick today. I wanted to start off- Hi, John. With the fourth quarter guidance here. We're, it's another sequential step down versus the third quarter, and you called out in the 10-Q filing that you're facing some sort of sales force disruptions, and you're expecting that to continue into the first half of 2024. I want to get a better sense of what's going on with the sales force and why you're expecting that disruption to continue into the first half of next year. Thanks, John. I'll take that. Just to take a step back for a moment, you know, we've been building and expanding our presence and commercial team in this market over many years now, really trying to establish that broad clinical footprint and get a lot of physicians going on this new therapy. And this year is really the pivot point where we're leveraging all that we've built over many years to really deepen adoption. At the same time, we continue to expand the commercial team. So we really understand this market and have gained, you know, tremendous learnings around what it takes to be successful. And we are executing that go deep strategy. We're doing work to strengthen referral networks. We're engaging allied healthcare professionals. We're doing lots of patient preference initiatives. But as we make that evolution, at the same time, that we're expanding our team, with those wins comes some, some choppiness, right? As we've got, you know, new, new territories and restructured territories and promotions and normal attrition. And so this is our area of focus going forward, where Chas and I are going to spend a lot of time with our, with our commercial and marketing and other leaders to really, learn from and, and double down on what's working well and reduce and mitigate, you know, the choppiness we've seen, which, you know, per the guidance and, and the Q, as you mentioned, we expect will, will persist, for a little bit of time until we hit our stride. That's helpful, Lucas. And Chas, maybe one for you. Coming into Silk, you talked a bit about what you're excited about. I just want to get a better sense of where your priorities are in the sense of optimizing the sales force, investing in new technologies. I just want to get a sense of what your vision is for this company and where your areas of focus are going to be. Yeah, no, thanks, John. I appreciate the question. Really, I'm not going to get into a lot of detail today. It truly is day five for me at this point. Except to reiterate, I really I did my homework, and I'm tremendously excited about the opportunity that we have. And clearly, as Lucas just said, we know we need to dig into some of the recent results and come forward with the kind of updates and you know, take a step back, very impressive growth that's happened over the time since launch, but now moving forward, kind of dig into that. So that'll be the obvious area to focus in on. And then beyond that, you know, I'm going to spend a lot of time getting to know the business, getting to know the team, spending time with customers. We're going to be at the Veith meeting next week, which many of our top customers will be at. You know, spending time digging in to learn what's made us so successful up to this point, and then what are the areas we need to do to focus on going forward. Thanks, Chas. That's helpful. Thanks for taking the questions. Stand by for our next question. Our next question comes from Robbie Marcus of JP Morgan. Robbie, please go ahead with your question. Hi, everyone. This is actually Rohan on for Robbie. Just want to say congrats, Chas, on the new role, and we look forward to working with you. Thank you. Just to start off, though, I'd just like to maybe ask you another question, piggybacking off of the last one. But is there anything kind of you can share just broadly about what excites you generally about the company? Obviously, making the move to come to Silk is pretty significant. It's obviously very different than Apollo as well. So maybe just talk about some of the ways you could leverage your experiences at Apollo with Silk, and then maybe just the drivers behind why you're so excited about this opportunity here. Sure. Yeah, thanks for the question. As I said, I did my homework, and as I talked to, you know, people throughout the industry and inclusive of customers and others, you know, when you take a step back, the benefits of the TCAR procedure are incredibly compelling. It's rare that you have the combination of benefits to patients, benefits for physicians, benefits to the healthcare system, with a lot of evidence to support that now out in the real world, with, you know, over 75,000 patients treated. And knowing that we still have a lot of room to run on that. And so I'm excited about that. It's a great organization, and I said in my comments, you know, all credit to Erica and Lucas and the team here for what they've built, and so it's really an honor to be a part of it. And I like the opportunity. And you mentioned Apollo, but also, you know, across my background, I've really enjoyed the challenges so changing behavior in healthcare is hard, right? There's a lot of inertia in the system, and so thinking through all of the different tools that we can use, whether it's education and training and patient programs and all the range of things, I've got a lot of different things in my background that I think I can call on. And to be clear, the team already here has done a lot of great stuff. So this is, this is adding to and enhancing what is already a very good commercial team. And I heard that loud and clear from many different stakeholders. But adding to that, so we can really go after that opportunity. I'm excited about it. Great. I guess the second question I had was more around kind of growth outlook for the remainder of this year and in 2024. Obviously, you called out some more pronounced seasonality in third quarter, and obviously, with the choppiness around the sales force, it's kind of led to a slowdown in growth. And given that kind of single-digit exit rate you're likely going to see in fourth quarter, how should we think about what a reasonable baseline is for 2024 and beyond, just in light of some of these puts and takes that you highlighted? Thanks, Rohan, for the follow-up question. I think we'll, you know, give Chas more than 5 days on the job to really dig in before we talk meaningfully about 2024. Obviously, I just commented on the 2023 guidance and some of the puts and takes. I think our long-term conviction about, you know, being very early in the penetration of this market, assembling a lot of the assets required for durable growth, you know, remain steadfast. And the goal now, again, is to really make that transition from broadening adoption to deepening adoption and get our sales team and our customers increasingly tenured together, as we drive these benefits for patients over many years to come. Okay, great. Thanks so much. Please stand by for our next question. Our next question, excuse me. Our next question comes from Joanne Wuensch of Citi. Hi, good afternoon. Joanne, please go ahead with your question. Good afternoon. This is Anthony on for Joanne. Thank you for taking our question. My first, Lucas, I think in your prepared remarks, you mentioned there were some pockets of weakness and demand. Can you maybe just elaborate, elaborate a bit more? Were these with certain types of doctors or certain geographies? Just any more granularity would be appreciated. Yeah. So we've, you know, talked recently about kind of where we stand at 80 territories in Q3 and 85 now in Q4, and roughly 2,600 physicians in Q3, which the math there is about 33 physicians per territory. So we have the ability to look at kind of per territory, per account, per physician metrics and understand, you know, what's going on for folks that are performing ahead of expectations, at expectations, or below expectations. So as we've done those forensics, we have each of those buckets, right? Territories and or docs and or hospital accounts that are ahead, at, or behind expectations. And so, you know, this is a business where, you know, 100 procedures is about $700,000 in revenue and across 80 territories. That's 1.25 procedures per territory, and that kind of moves the business incrementally in a positive way. And if we miss that opportunity for a procedure or two or three because there's some sort of change or disruption at the local level, there are some opportunities we missed, right? And so that's really some of the color and context for my comments. helpful. Thank you. And then, can you just give an update, on where you are in China and Japan? I think on the last earnings call, you said you were, just about to submit for, reimbursement in Japan, but just any additional color would be appreciated. Yeah, we didn't mention on the call because there really is no substantive update. Just as a reminder, you know, TCAR is multiple products, which means multiple regulatory pathways across two different countries. It also means multiple reimbursement pathways as well as the, the channel discussions. And so we continue to make good progress on all those fronts as the markets themselves are dynamic, and changing. And so no, no substantive update, this quarter, but continue to make progress. Great. Appreciate the color. Please hold for our next question. Our next question comes from Neil Chatterji of B. Riley. Neil, go ahead with your question. Neil, go ahead with your question. Stand by for our next question. Our next question comes from Adam Maeder of Piper Sandler. Adam, please go ahead with your question. Hi, good afternoon, Chas and Lucas. Thank you for taking the questions. Chas, congrats on the new role. Thanks, Adam. Maybe just to start, wanted to double-click a little bit more on the sales disruption issue, and just understand, you know, kind of where are we today from a headcount standpoint? I mean, I just, I heard the commentary on territories, but are you willing to give headcount? Where were we at the beginning of the year? You know, do you have any territories that are, you know, understaffed or open? Just any more details, you know, you can share there would be appreciated. Thanks. Sure, Adam. I'll take that. So we exited 2022 with 70 territories, as you may remember, which was similar spot where we were in Q2 and then Q3, 80, and I just mentioned 85 on this call. And we are roughly a territory for us is one sales rep and one clinical specialist on average, and then obviously we have a sales management layer in addition. And so as we've been building and expanding this team over time, at any given point in time, we're doing territory splits, we're backfilling reps who've been promoted. There's always normal attrition and open territories either because of attrition or promotion. And so that's kind of always happening in the background and over our entire commercial existence. But that's where we stand today. Okay. Thanks for the additional color there. And, I guess just for the follow-up would be on the NCD that, you know, went into place last month. I'm just curious what you're hearing from your customer base about the new carotid NCD. You know, any kind of chatter that they may be sharing with you all? Have they seen any change to the referral pathway or volume trends? Thank you. Yeah, I think there's general excitement and, I think, you know, physicians talking about this, referring physicians talking about this, companies and innovators talking about this is all a good thing for the market as a whole. As I said in my prepared remarks, our position hasn't changed. We think this, you know, as stated, one of the goals by Medicare is to broaden access, and we think this leads to more interest and awareness that could potentially have a market expansion effect over time. And we really are at the beginning after you know, many years of putting TCAR on the map and in the history of transfemoral carotid stenting prior to that, you know, at the era of minimally invasive carotid stenting, which has already happened in almost every other blood vessel, right? And so we see, we see the market expanding, we see minimally invasive carotid stenting procedures rising and invasive surgical procedures falling, and we are the clear leader in the minimally invasive category, right? As measured by evidence, experience, products, broad label, commercial expertise, and on and on. So we're excited about this next era. Thank you. Stand by for our next question. Our next question comes from Kristen Stewart of CL King. Kristin, please go ahead with your question. Hi, thanks for taking my question. Chas, congratulations on the new role. Thank you. I was wondering if you could just dive a little bit deeper into the expectations for Q4, to what extent there's any sort of disruption that you would expect from the NCD embedded in your assumptions there? Well, I think it's certainly a new variable, Kristin. So that's, that's, you know, something has to be considered for that. Some of it is kind of where our commercial organization is, as I mentioned, and some of it is just making sure Chas has the time to really dig into the business, as we close out the year. Okay. And then as a follow-up question, just on gross margins, they came in improved sequentially. I was wondering if you could help us just take a step back and think about what sort of expectations we should see going forward. Yeah. So it was a strong, kind of clean quarter on the gross margin front, relative to volume across our two manufacturing facilities that are fully operational, and so we expect to continue getting some leverage out of that fixed overhead as we drive unit volumes up over the future. And we've also obviously continued to perform really well on the product level ASPs that obviously help underwrite that performance in the face of the supply chain cost, inflationary pressures and other things that serve as headwinds. Okay, thanks very much. Thank you, Kristen. One moment for our next question. Our next question comes from Suraj Kalia of Oppenheimer & Company. Suraj, go ahead with your question. Good afternoon, Chas, Lucas. Can you hear me all right? Yes. Yes. Good afternoon, Suraj. Perfect. Chas, congrats on the new role. Wish you all the best. Thank you. So, Chas, I just, forgive me, I know you're new, and this question might be unfair, but I just want to sort of tee off on your comments about doing due diligence on Silk. When you look back at your background with Apollo, Torax, so on and so forth, when such a structural shift happens, do you think it makes any sense to change salesforce incentives either to reduce churn and or improve utilization? Okay, you're getting real detailed on me, Suraj. You know, look. Forgive me, I. I appreciate the question, and let me, you know, just say so, again, in the broader context, the commercial team here has done a fantastic job of growing the business since launch. And, you know, as we look at and learn from what's happened this year, we're gonna dig into all of that, right? We're gonna spend time together looking at it collectively and say, what are the various aspects that we need to do? What do we build on that's already in place, that's working great? What are some areas we may wanna adjust and enhance going forward? But I am nowhere near being able to answer the question in terms of exactly what we might do until we've had a chance to do that. And so I really do look forward, in the coming months, to coming back to this group with much more of a forward-looking commentary on where we're heading. But first I got to do the work. Fair enough. Hey, Lucas, one follow-up question for you, and I'll hop back in queue. In your prepared remarks, you mentioned about, you know, and I'm paraphrasing here, mining physician behavior to see how to better engage the physician. Again, I'm paraphrasing. What I'm curious about, Lucas, is given the newness of the NCD, do we have enough data points to mine any changes in physician behavior, hence, make any corrective actions? Gentlemen, thank you for taking my questions. Thanks for the question, Suraj. I think it has less to do with reimbursement in this disease state. As we've always said, the brain is the end organ here, which is incredibly unforgiving. And what could go wrong in a prophylactic procedure intended to prevent a future stroke is major stroke, death, heart attack, permanent cranial nerve injury. So the stakes are really high, and physician behavior is derivative of, you know, what's at stake, and confidence has a lot to do with it. And when we say the inertia of CEA, that's another way of saying, you know, their confidence in a procedure that they've performed for a long time. And so that's the same type of confidence and the same type of barriers to entry we'll ultimately build around TCAR. The good news is, we know we can do it because we've done it, right? We've got a lot of TCAR-first physicians that have crossed that chasm and have really gone from, you know, not confident to highly confident, and that's reflective in their adoption patterns. So when we talk about behavior, it's really confidence and other key variables that allow us to look at adoption trends and what's working really well, what's not working so well, and how do we continue to change and evolve to drive the business in this disease state with this indicator. Thank you. Stand by for our next question. This question comes from Michael Polark of Wolfe Research. Michael, please go ahead with your question. Thank you. Two for me. One, the balloon. Lucas, would you be willing to frame up numerically how much balloon contribution, year-to-date? Thanks for the question, Mike. So I'd say we're slightly ahead on our ASP expectations and slightly behind on our utilization expectations, and obviously, those two things are related. And so that is. There's still a lot of room to run in terms of driving the balloon utilization in more accounts and more procedures. So we're making good progress, but no, we don't break out product-level detail, Mike. The follow-up, maybe for Chas, and maybe again, five days in a question that's unfair. So if that's the answer, that's the answer. But, you know, I look at Silk, and I, you know, I know there's nuances here, but your customers are principally the vascular surgeon community, and this NCD kind of levels the playing field with interventionalists. And I guess, as you look at this at a really high level with multi-year lens, doing the diligence ahead of saying yes to the job, do you think there's a path here where Silk, in addition to continuing to serve the surgical community, engages with interventionalists in a bigger way? I appreciate the question. And we are gonna look at, over time, broadly, a whole range of strategic options of where we wanna be over time, if you take a lens of, you know, multi-year. And we're gonna have those discussions. So, you know, allow me to spend time with the team, really understanding, experience to date as well as other plans. You know, I like the fact that right now we are a, you know, pretty focused company, and we gotta focus on that and keep it going. But then I also like the fact that that creates new opportunities for growth down the line, and that could be international opportunities or it could be, you know, adjacent opportunities. But at this point, what that looks like, I'm not prepared to sort of put a stake in the ground. We'll – and there's, by the way, already been a fair amount of work done internally, so I'm gonna learn from that, understand where we're thinking about where it could go, and then come back to you guys with a more robust comprehensive plan. Thank you. One moment for our next question. Our question comes from Neil Chatterji of B. Riley. Neil, please go ahead with your question. Seeing there are no further questions, I'd like to turn it back over to Chas McKhann for closing remarks. Yeah, thank you for joining us today. I just wanna leave you with some final thoughts, especially as we pull back just from reporting on the quarter. TCAR truly is an outstanding procedure. There are the proven benefits for patients, physicians, and the healthcare system, as well as the support of the really robust clinical evidence, is really unmatched in this space. And at Silk Road, because of all of that, we aspire, and this hasn't changed at all, to establish TCAR as the standard of care in the treatment of chronic CAD disease. We believe that patients deserve the benefits of this therapy. The company has made a lot of progress towards achieving that objective over time, and we have a strong team in place. Going forward, as I mentioned a few times, we're gonna really dig into the business and work to deliver on that promise of this therapy. To all of our investors, we very much appreciate your support and look forward to sharing more in the coming months. Thank you all for joining us today. Thank you for your participation in today's conference. This does conclude the program. You may now disconnect.